View Filing Data

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2015	Aug. 11, 2015
Document and Entity Information
Entity Registrant Name	OptimizeRx Corp
Entity Central Index Key	0001448431
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		22,949,819

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 3,645,878	$ 3,446,973
Accounts receivable	1,918,419	2,100,381
Prepaid expenses	76,376	28,093
Total Current Assets	5,640,673	5,575,447
Property and equipment, net	10,674	12,813
Other Assets
Patent rights, net	901,491	930,854
Web development costs, net	424,075	504,643
Security deposit	5,049	5,049
Total Other Assets	1,330,615	1,440,546
TOTAL ASSETS	6,981,962	7,028,806
Current Liabilities
Accounts payable - trade	172,183	200,372
Accounts payable - related party	570,000	570,000
Accrued expenses	9,851	25,459
Revenue share payable	1,190,995	1,502,761
Deferred revenue	336,213	120,130
Total Liabilities	2,279,242	2,418,722
Stockholders' Equity
Common stock, $.001 par value, 500,000,000 shares authorized, 22,949,819 and 22,867,319 shares issued and outstanding, respectively	22,950	22,867
Preferred stock, $.001 par value, 10,000,000 shares authorized, no shares issued and outstanding
Stock warrants	2,153,295	2,153,295
Additional paid-in-capital	27,806,253	27,595,609
Stock payable	1,132,148	963,063
Deferred stock compensation	(18,750)
Accumulated deficit	(26,393,176)	(26,124,750)
Total Stockholders' Equity	4,702,720	4,610,084
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 6,981,962	$ 7,028,806

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	22,949,819	22,867,319
Common stock, shares outstanding	22,949,819	22,867,319
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
NET REVENUE	$ 1,705,457	$ 1,426,808	$ 3,193,010	$ 2,716,236
REVENUE SHARE EXPENSE	882,327	730,140	1,638,768	1,291,551
GROSS MARGIN	823,130	696,668	1,554,242	1,424,685
OPERATING EXPENSES	980,659	896,529	1,823,269	2,386,747
INCOME (LOSS) FROM OPERATIONS	(157,529)	(199,861)	(269,027)	(962,062)
OTHER INCOME (EXPENSE)
Interest income	304	223	601	329
TOTAL OTHER INCOME (EXPENSE)	304	223	601	329
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES	(157,225)	(199,638)	(268,426)	(961,733)
PROVISION FOR INCOME TAXES
NET INCOME (LOSS)	$ (157,225)	$ (199,638)	$ (268,426)	$ (961,733)
WEIGHTED AVERGE NUMBER OF SHARES OUTSTANDING
BASIC	22,924,819	23,241,707	22,917,678	20,355,651
DILUTED
NET INCOME (LOSS) PER SHARE
BASIC	$ (0.01)	$ (0.01)	$ (0.01)	$ (0.05)
DILUTED

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period	$ (268,426)	$ (961,733)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	159,337	115,828
Stock and options issued for services	361,062	627,354
Changes in:
Accounts receivable	181,962	302,202
Prepaid expenses	(48,283)	(30,198)
Accounts payable	(28,189)	203,714
Revenue share payable	(311,766)	(414,563)
Accrued expenses	(15,608)	(12,000)
Deferred revenue	216,083	19,651
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	246,172	(149,745)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(1,592)
Patent rights	(4,517)	(92,624)
Website site development costs	(42,750)	(119,616)
NET CASH USED IN INVESTING ACTIVITIES	(47,267)	(213,832)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock		10,000,000
Equity issuance costs		(1,204,968)
Purchase of common and preferred stock and warrants		(6,000,000)
NET CASH PROVIDED BY FINANCING ACTIVITIES		2,795,032
NET INCREASE IN CASH AND CASH EQUIVALENTS	198,905	2,431,455
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	3,446,973	1,118,243
CASH AND CASH EQUIVALENTS - END OF PERIOD	3,645,878	3,549,698
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest
Cash paid for income taxes

Nature of Business and Basis of Presentation	6 Months Ended
Nature of Business and Basis of Presentation	Jun. 30, 2015
Nature of Business and Basis of Presentation [Abstract]
NATURE OF BUSINESS AND BASIS OF PRESENTATION	NOTE 1 – NATURE OF BUSINESS AND BASIS OF PRESENTATION OptimizeRx Corporation is a technology solution company focused on the health care industry. Its objective is to bring better access to better care by leveraging its proprietary technology to provide on demand savings and support within physicians and patients web based platforms, including Electronic Health Records and Patient Portals. Initially defined as a marketing and advertising company through its consumer website, OptimizeRx.com, the Company has matured as a technology solutions provider through its direct to physician solution, SampleMD. SampleMD allows physicians to automatically display and distribute sample vouchers and/or co-pay coupons electronically within the ePrescription platform to pharmacies on behalf of their patients. The SampleMD solution is integrated into the ePrescribing or Electronic Medical Records applications, but can also sit on a prescriber’s desktop. OptimizeRx solutions provide health care institutions with an alternative option to the traditional hassles and issues associated with storing and managing physical drug samples and pre-printed coupons and it provides better access and affordability to patients to improve affordability, adherence and outcomes. In turn, OptimizeRx provides pharmaceutical manufacturers with both direct to consumer and direct to physician channels for more efficiently communicating and promoting their products and savings. The consolidated financial statements for the three and six month periods ended June 30, 2015 and 2014 have been prepared by us without audit pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, all adjustments necessary to present fairly our financial position, results of operations, and cash flows as of June 30, 2015 and 2014, and for the periods then ended, have been made. Those adjustments consist of normal and recurring adjustments. The consolidated balance sheet as of December 31, 2014, has been derived from the audited consolidated balance sheet as of that date. Certain information and note disclosures normally included in our annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with a reading of the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as filed with the U.S. Securities and Exchange Commission. The results of operations for the three and six month periods ended June 30, 2015, are not necessarily indicative of the results to be expected for the full year. Certain reclassifications have been made in the prior period’s consolidated financial statements to conform to the current period’s presentation.

Stockholders Equity	6 Months Ended
Stockholders Equity	Jun. 30, 2015
Stockholders Equity [Abstract]
STOCKHOLDERS EQUITY	NOTE 2 – STOCKHOLDERS EQUITY In January 2015, we issued 12,500 shares of common stock to outside Directors in connection with our Director Compensation plan, which calls for issuance of 6,250 shares per quarter for each Director. Those shares were recorded as stock payable at December 31, 2014. In addition, we recorded an additional 12,500 shares, valued at $16,375 as stock payable at March 31, 2015 for shares to be issued in April 2015 and 12,500 shares, valued at $13,375 were issued in June 2015 for the second quarter payment. In February 2015, we entered into a capital markets advisory agreement covering a one year period, which called for 90,000 shares of common stock to be issued as compensation. These shares were valued at $112,500 and are being amortized to expense over the period of service. 45,000 of these shares were issued in March 2015, with the balance to be issued in August 2015. The agreement was terminated in July 2015, effective in August, and the remaining 45,000 shares will not be issued. The total expense to be recognized will be $56,250 and is being amortized over the period the agreement is in effect. In March 2014, we entered into a securities purchase agreement, pursuant to which we sold 8,333,333 shares of our common stock for $1.20 per share, or gross proceeds of $10,000,000. Placement agents in the offering received commissions equal to approximately 9.7% of gross proceeds, for an aggregate commission of approximately $970,000, including reimbursements for their reasonable out of pocket expenses. Placement agents also received warrants to purchase up to 804,139 shares of our common stock with an exercise price of $1.20 per share and a term of 5 years. The warrants were valued at $1,110,211, have been recorded as equity issuance costs, and were registered on a registration statement that went effective May 28, 2014. In addition to the warrants to placement agents, we also paid cash bonuses of $240,000 to three executive officers, agreed to issue 200,000 shares to three executive officers, and issued 150,000 shares to a consultant, in connection with the equity raise. The stock was valued based on the fair market value on the grant date, which was $630,000 in total. These amounts have been recorded as equity issuance costs, resulting in total equity issuance costs of $2.95 million. The 200,000 shares for the three executive officers have not been issued, but are recorded as stock payable and can be requested by the executive officers at any time. We used the net proceeds of the offering to exercise the securities redemption option agreement, as amended, with Vicis Capital Master Fund that provided us with an option to purchase all of the outstanding shares and derivative securities held by Vicis for total payment of $6,000,000. The shares and derivative securities included the Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Common Stock, and warrants to purchase shares of common stock held by Vicis in the Company. The balance of the net proceeds were used for working capital purposes. In January 2014, an executive officer exercised 500,000 stock warrants using the cashless exercise feature included in the warrants. In exchange for the 500,000 warrants, 410,348 shares of common stock were issued. In June 2015, we agreed to grant 197,605 fully vested shares of our common stock to two executive officers as bonuses. These shares have not been issued, but are recorded as stock payable and can be requested by the officers at any time. In February 2014, we agreed to grant 337,500 shares of our common stock, half of which vested immediately and half of which vested in August 2014, to two executive officers as bonuses based on their efforts to recapitalize the company to secure approximately $3 million in working capital while reducing fully diluted shares by approximately 7 million shares. These shares have not been issued, but are recorded as stock payable and can be requested by the officers at any time.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Share Based Payments - Options	6 Months Ended
Share Based Payments - Options	Jun. 30, 2015
Share Based Payments - Options [Abstract]
SHARE BASED PAYMENTS - OPTIONS	NOTE 3 – SHARE BASED PAYMENTS – OPTIONS We use the fair value method to account for stock based compensation. We recorded $110,039 and $170,611 in compensation expense in the periods ended June 30, 2015 and 2014, respectively, related to options issued under our stock-based incentive compensation plan. This includes expense related to options issued in prior years for which the requisite service period for those options includes the current year, options granted in the current year and options repriced in the current year. The fair value of these instruments was calculated using the Black-Scholes option pricing model. Information related to the assumptions used in this model is set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2015

Commitments and Contingencies [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 4 – COMMITMENTS AND CONTINGENCIES

Litigation

The company is currently involved in the following legal proceedings.

In September 2014, we initiated litigation against Shadron Stastney, the Company’s previous CEO, in the U.S. District Court in the Eastern District of Michigan as a result of a dispute related to his separation agreement. Mr. Stastney alleged damages related to the non-registration of shares that he was granted as part of his separation agreement signed in September 2013. Under the terms of the contract we are not obligated to register the shares and we deny any obligation to do so. We have requested declarative relief from the court and also requested an injunction from the court preventing Mr. Stastney from continuing to pursue his claims. Mr. Stastney has filed a counterclaim requesting damages of $450,000 related to the nonregistration of his shares. The parties are currently in the discovery process.

In March 2015, we initiated litigation against LDM Group, LLC and PDR Network, LLC in the U.S. District Court in the Eastern District of Missouri related to the breach by LDM, and PDR as successor, of the settlement agreement signed February 28, 2014 related to previous litigation with LDM. LDM has failed to live up to its obligations under the settlement agreement including, but not limited to, not allowing us to distribute our eCoupon programs in the LDM network, not allowing us to distribute the LDM patient education programs, and not providing other information required under the settlement agreement. We are seeking enforcement of the settlement agreement and we are seeking damages in an amount at least equal to the amounts paid to date to LDM under the settlement agreement, which approximates $1.0 million, as well as damages for lost income and business value as a result of LDM’s breach of the agreement.

In March 2015, we also initiated litigation against PDR Network, LLC in the U.S. District Court in the District of New Jersey as a result of PDR’s breach of the Master Services Agreement between the parties requiring PDR to exclusively use our eCoupon solution. We assert that PDR’s acquisition of LDM and the use of the LDM network to distribute coupons by PDR violates the agreement between the parties and we are seeking damages in an amount at least equal the amounts paid to date by us to LDM under the settlement agreement, which approximates $1.0 million, as well as damages for lost income and business value as a result of PDR’s actions.

In May 2015, we filed an amended complaint in the Missouri case to consolidate the two cases and withdrew the case against PDR Networks in the U.S. District Court in the District of New Jersey, without prejudice.

In July, 2015, the U.S. District Court for the Eastern District of Missouri dismissed the case, citing lack of Federal jurisdiction in the matter. We are in the process of refiling the consolidated case against PDR Network and LDM group in State court in Missouri.

Restatement

6 Months Ended

Jun. 30, 2015

Restatement [Abstract]

RESTATEMENT

NOTE 5 – RESTATEMENT

We restated our financial statements to correct the way we accounted for certain items related to stock based compensation, revenue share expense, and revenue recognition. The full impact of the restatement was reflected in the December 31, 2014 financial statements at the end of the year. The table below reflects the impact on the 2014 period reflected in this report.

The restated Consolidated Statement of Operations and Consolidated Statement of Cash Flows for the three and six months ended June 30, 2014, as applicable, is as follows:

Three months ended June 30, 2014					Previously
Financial Statement	Line Item	Corrected			Stated
Income statement	Revenue		1,426,808			1,454,214
Income statement	Cost of Sales	$	730,140		$	540,048
Income statement	Operating expenses		896,529			967,070
Income statement	Loss from operations	$	(199,861	)	$	(52,904	)
Income statement	Loss before income taxes	$	(199,638	)	$	(52,681	)
Income statement	Net loss	$	(199,638	)	$	(52,681	)

Six months ended June 30, 2014					Previously
Financial Statement	Line Item	Corrected			Stated
Income statement	Revenue		2,716,236			2,771,560
Income statement	Cost of Sales	$	1,291,551		$	1,038,858
Income statement	Operating expenses		2,386,747			2,439,028
Income statement	Loss from operations	$	(962,062	)	$	(706,326	)
Income statement	Loss before income taxes	$	(961,733	)	$	(705,996	)
Income statement	Net loss	$	(961,733	)	$	(705,996	)
Statement of cash flows	Net loss	$	(961,733	)	$	(705,996	)
Statement of cash flows	Stock and options issued for services	$	627,344		$	654,634
Statement of cash flows	Increase in accounts payable	$	203,714		$	173,889
Statement of cash flows	Decrease in revenue share payable	$	(311,776	)	$	(686,760	)
Statement of cash flows	Increase in deferred revenue	$	19,651		$	38,656

Restatement (Tables)

6 Months Ended

Jun. 30, 2015

Restatement [Abstract]

Schedule of restatement

Three months ended June 30, 2014					Previously
Financial Statement	Line Item	Corrected			Stated
Income statement	Revenue		1,426,808			1,454,214
Income statement	Cost of Sales	$	730,140		$	540,048
Income statement	Operating expenses		896,529			967,070
Income statement	Loss from operations	$	(199,861	)	$	(52,904	)
Income statement	Loss before income taxes	$	(199,638	)	$	(52,681	)
Income statement	Net loss	$	(199,638	)	$	(52,681	)

Six months ended June 30, 2014					Previously
Financial Statement	Line Item	Corrected			Stated
Income statement	Revenue		2,716,236			2,771,560
Income statement	Cost of Sales	$	1,291,551		$	1,038,858
Income statement	Operating expenses		2,386,747			2,439,028
Income statement	Loss from operations	$	(962,062	)	$	(706,326	)
Income statement	Loss before income taxes	$	(961,733	)	$	(705,996	)
Income statement	Net loss	$	(961,733	)	$	(705,996	)
Statement of cash flows	Net loss	$	(961,733	)	$	(705,996	)
Statement of cash flows	Stock and options issued for services	$	627,344		$	654,634
Statement of cash flows	Increase in accounts payable	$	203,714		$	173,889
Statement of cash flows	Decrease in revenue share payable	$	(311,776	)	$	(686,760	)
Statement of cash flows	Increase in deferred revenue	$	19,651		$	38,656

Stockholders Equity (Details) - USD ($)	1 Months Ended						3 Months Ended	6 Months Ended
Stockholders Equity (Details) - USD ($)	Jul. 31, 2015	Feb. 28, 2015	Jan. 31, 2015	Mar. 31, 2014	Feb. 28, 2014	Jan. 31, 2014	Jun. 30, 2015	Jun. 30, 2015	Mar. 31, 2015
Sharehoders equity [Texual]
Common stock issued for equity issuance costs								$ 630,000
Employee bonus, Share					$ 337,500
Additional working capital					$ 3,000,000
Fully diluted shares					7,000,000
Equity issuance cost								2,950,000
Capital markets advisory agreement [Member]
Sharehoders equity [Texual]
Called for issuance of shares		90,000
Additional shares issued									45,000
Called for issuance of shares, values		$ 112,500
Subsequent Event [Member] \| Capital markets advisory agreement [Member]
Sharehoders equity [Texual]
Number of shares not be issued	45,000
Called for issuance of shares, values	$ 56,250
Securities Purchase Agreement [Member]
Sharehoders equity [Texual]
Sale of comman stock shares				8,333,333
Sale of common stock value				$ 10,000,000
Sale of stock price per share				$ 1.20
Placement Agents [Member]
Sharehoders equity [Texual]
Warrant exercise price period				5 years
Commissions percentage				9.70%
Commissions				$ 970,000
Purchase of warrants				804,139
Warrants, Value				$ 1,110,211
Exercise price				$ 1.20
Three Officers [Member]
Sharehoders equity [Texual]
Additional shares issued				200,000
Employee Bonus				$ 240,000
Consultant [Member]
Sharehoders equity [Texual]
Additional shares issued				150,000
Vicis [Member]
Sharehoders equity [Texual]
Debt redemption, amount							$ 6,000,000	$ 6,000,000
Officer [Member]
Sharehoders equity [Texual]
Additional shares issued						410,348
Warrants exercised, number of shares						500,000
Outside director [Member]
Sharehoders equity [Texual]
Called for issuance of shares			6,250
Additional shares issued			12,500
Additional shares issued							12,500	12,500
Additional shares issued, value							$ 16,375	$ 13,375
Two Officers [Member]
Sharehoders equity [Texual]
Employee bonus, Share								$ 197,605

Share Based Payments - Options (Details) - USD ($)	6 Months Ended
Share Based Payments - Options (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Share based payments options [Textual]
Stock-based compensation expense	$ 110,039	$ 170,611

Commitments and Contingencies (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Commitment and contingencies [Textual]
Claims pertaining to damages to nonregistration of shares		$ 450,000
Damage related to LDM' s breach of the agreement.	$ 1,000,000

Restatement (Details) - USD ($)	3 Months Ended		6 Months Ended
Restatement (Details) - USD ($)	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Class of Stock [Line Items]
Revenues	$ 1,705,457	$ 1,426,808	$ 3,193,010	$ 2,716,236
COST OF SALES		730,140	756,440	1,291,551
Operating expenses	980,659	896,529	1,823,269	2,386,747
Loss from operations	(157,529)	(199,861)	(269,027)	(962,062)
Loss before income taxes	(157,225)	(199,638)	(268,426)	(961,733)
Net loss	$ (157,225)	(199,638)	(268,426)	(961,733)
Net loss				(961,733)
Stock and options issued for services			361,062	627,354
Increase in accounts payable			(28,189)	203,714
Decrease in revenue share payable			311,766	414,563
Increase in deferred revenue			$ 216,083	19,651
Previously Stated
Class of Stock [Line Items]
Revenues		1,454,214		2,771,560
COST OF SALES		540,048		1,038,858
Operating expenses		967,070		2,439,028
Loss from operations		(52,904)		(706,326)
Loss before income taxes		(52,681)		(705,996)
Net loss		$ (52,681)		(705,996)
Net loss				(705,996)
Stock and options issued for services				654,634
Increase in accounts payable				173,889
Decrease in revenue share payable				(686,760)
Increase in deferred revenue				$ 38,656